The Transition to Medication Adoption in Publicly Funded Substance Use Disorder Treatment Programs: Organizational Structure, Culture, and Resources

Abstract

ABSTRACT. Objective: Medications for the treatment of substance use disorders (SUDs) are not widely available in publicly funded SUD treatment programs. Few studies have drawn on longitudinal data to examine the organizational characteristics associated with programs transitioning from not delivering any pharmacotherapy to adopting at least one SUD medication. Method: Using two waves of panel longitudinal data collected over a 5-year period, we measured the transition to medication adoption in a cohort of 190 publicly funded treatment organizations that offered no SUD medications at baseline. Independent variables included organizational characteristics, medical resources, funding, treatment culture, and detailing activities by pharmaceutical companies. Results: Of 190 programs not offering SUD pharmacotherapy at baseline, 22.6% transitioned to offering at least one SUD medication at follow-up approximately 5 years later. Multivariate logistic regression results indicated that the employment of at least one physician at baseline, having a greater proportion of Medicaid clients, and pharmaceutical detailing were positively associated with medication adoption. Conclusions: Adoption of pharmacotherapy was more likely in programs that had greater medical resources, Medicaid funding, and contact with pharmaceutical companies. Given the potential expansion of Medicaid under the Affordable Care Act, patients served by publicly funded programs may gain greater access to such treatments, but research is needed to document health reform's impact on this sector of the treatment system. (J. Stud. Alcohol Drugs, 75, 476-485, 2014)

Prevention, screening, and treatment for heavy drinking and alcohol use disorder

“…189 Regarding the uptake of MAT, a study among a U.S. cohort of 190 publicly-funded treatment organizations that offered no substance use disorder (SUD) medications at baseline showed that 23% offered SUD medications after five years of follow-up. 190 This was more likely to occur in programs that had greater medical resources, Medicaid funding, and contact with pharmaceutical companies. 190…”

Medicaid, Private Insurance, and the Availability of Smoking Cessation Interventions in Substance Use Disorder Treatment

“…Medicaid revenues are positively associated with both the adoption (i.e., any use) and implementation (i.e., extent of use) of such medications (35, 36). Comparisons of privately funded treatment programs to those that rely on governmental grants and contracts have revealed sizeable differences in adoption of medications (36, 37), while the percentage of patients insured by health maintenance organizations (HMOs) is positively associated with the adoption of naltrexone (38). These studies suggest that Medicaid and private insurance revenues may be associated with smoking cessation pharmacotherapy.…”

Comparing rating paradigms for evidence-based program registers in behavioral health: Evidentiary criteria and implications for assessing programs

“…Of course broad-based legislation or policies are being evaluated, but using evaluation paradigms that do not follow the orthodox Campbellian model, but rather an econometric approach, for instance. (Gu et al, 2014; Greene et al, 2014; Abraham, 2014; Wagner et al, 2014, Knudsen and Roman, 2014). The problem is that such non-experimental evaluations would either not be eligible for inclusion or would rank low in a registers’ current rating schemes.…”